Cholinergic antagonist 3-quinuclidinyl benzilate - Impact on learning and memory in Wistar rats

Behavioural Brain Research

Volumn 266, Issue , 2014, Pages 193-200

  Misik, Jan ^a   Vanek, Jan ^b   Musilek, Kamil ^a   Kassa, Jiri ^a  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

Author keywords

Acquisition; Consolidation; Muscarinic receptors; Passive avoidance; Retrieval; Water maze

Indexed keywords

QUINUCLIDINYL BENZILATE; MUSCARINIC RECEPTOR BLOCKING AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MODEL; INFORMATION RETRIEVAL; LATENT PERIOD; LEARNING; LOCOMOTION; LONG TERM MEMORY; MALE; MEMORY; MEMORY CONSOLIDATION; MORRIS WATER MAZE TEST; NONHUMAN; PASSIVE AVOIDANCE TEST; PRIORITY JOURNAL; RAT; ROTAROD TEST; SWIMMING; TASK PERFORMANCE; WISTAR RAT; ANALYSIS OF VARIANCE; ANIMAL; AVOIDANCE BEHAVIOR; CHEMICALLY INDUCED; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; LEARNING DISORDER; MAZE TEST; MOTOR ACTIVITY; NONPARAMETRIC TEST; RECALL; TIME; TOXICITY;

ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LEARNING DISORDERS; MALE; MAZE LEARNING; MENTAL RECALL; MOTOR ACTIVITY; MUSCARINIC ANTAGONISTS; QUINUCLIDINYL BENZILATE; RATS; RATS, WISTAR; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84897877777     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2014.03.001     Document Type: Article

References (48)

1. Schliebs R., Arendt T. The cholinergic system in aging and neuronal degeneration. Behav Brain Res 2011, 221:555-563.
2. McNamara R.K., Skelton R.W. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res Brain Res Rev 1993, 18:33-49.
3. D'Hooge R., De Deyn P.P. Applications of the Morris water maze in the study of learning and memory. Brain Res Brain Res Rev 2001, 36:60-90.
4. Tinsley C.J., Fontaine-Palmer N.S., Vincent M., Endean E.P., Aggleton J.P., Brown M.W., et al. Differing time dependencies of object recognition memory impairments produced by nicotinic and muscarinic cholinergic antagonism in perirhinal cortex. Learn Mem 2011, 18:484-492.
5. De-Mello N., Carobrez A.P. Elevated T-maze as an animal model of memory: effects of scopolamine. Behav Pharmacol 2002, 13:139-148.
6. Bymaster F.P., Heath I., Hendrix J.C., Shannon H.E. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 1993, 267:16-24.
7. von Linstow Roloff E., Harbaran D., Micheau J., Platt B., Riedel G. Dissociation of cholinergic function in spatial and procedural learning in rats. Neuroscience 2007, 146:875-889.
8. Klinkenberg I., Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Behav Rev 2010, 34:1307-1350.
9. Doguc D.K., Delibas N., Vural H., Altuntas I., Sutcu R., Sonmez Y. Effects of chronic scopolamine administration on spatial working memory and hippocampal receptors related to learning. Behav Pharmacol 2012, 23:762-770.
10. Buccafusco J.J., Terry A.V., Webster S.J., Martin D., Hohnadel E.J., Bouchard K.A., et al. The scopolamine-reversal paradigm in rats and monkeys: the importance of computerassisted operant-conditioning memory tasks for screening drug candidates. Psychopharmacology 2008, 199:481-494.
11. Lenz R.A., Baker J.D., Locke C., Rueter L.E., Mohler E.G., Wesnes K., et al. The scopolamine model as a pharmacodynamic marker in early drug development. Psychopharmacology 2012, 220:97-107.
12. Kinney H.C., Panigrahy A., Rava L.A., White W.F. 3-Dimensional distribution of [H3] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in the developing human brain-stem. J Comp Neurol 1995, 362:350-367.
13. Haga K., Kruse A.C., Asada H., Yurugi-Kobayashi T., Shiroishi M., Zhang C., et al. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 2012, 482:547-551.
14. Fusek J., Bajgar J., Kassa J., Kuca K., Jun D. Psychotomimetic agent BZ (3-quinuclidinyl benzilate). Handbook of toxicology of chemical warfare agents 2009, 135-142. Elsevier, London. R.C. Gupta (Ed.).
15. Mansfield K.J., Liu L., Mitchelson F.J., Moore K.H., Millard R.J., Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes with ageing. Br J Pharmacol 2005, 144:1089-1099.
16. Lee K.S., Nishimune A., Yoshiki H., Anisuzzaman A.S., Suzuki F., Wang M.H., et al. Assessment of novel muscarinic acetylcholine receptors in rat cerebral cortex by a tissue segment binding method. J Pharmacol Sci 2010, 112:444-451.
17. Mezey S.Z., Szekely A.D., Bourne R.C., Kabai P., Csillag A. Changes in binding to muscarinic and nicotinic cholinergic receptors in the chick telencephalon, following passive avoidance learning. Neurosci Lett 1999, 270:75-78.
18. Krejcova G., Patocka J., Slaninova J. Effect of humanin analogues on experimentally induced impairment of spatial memory in rats. J Pept Sci 2004, 10:636-639.
19. Kunesova G., Hlavacek J., Patocka J., Evangelou A., Zikos C., Benaki D., et al. The multiple T-maze in vivo testing of the neuroprotective effect of humanin analogues. Peptides 2008, 29:1982-1987.
20. Deiana S., Platt B., Riedel G. The cholinergic system and spatial learning. Behav Brain Res 2011, 221:389-411.
21. Micheau J., Marighetto A. Acetylcholine and memory: a long, complex and chaotic but still living relationship. Behav Brain Res 2011, 221:424-429.
22. Robinson L., Platt B., Riedel G. Involvement of the cholinergic system in conditioning and perceptual memory. Behav Brain Res 2011, 221:443-465.
23. Huang Z.B., Wang H., Rao X.R., Zhong G.F., Hu W.H., Sheng G.Q. Different effects of scopolamine on the retrieval of spatial memory and fear memory. Behav Brain Res 2011, 221:604-609.
24. Stuchlik A., Petrasek T., Hatalova H., Rambousek L., Nekovarova T., Vales K. Behavioral tests for evaluation of information processing and cognitive deficits in rodent animal models of neuropsychiatric disorders. Schizophrenia in the 21st century 2012, 153-180. InTech, Rijeka. T.H.J. Burne (Ed.).
25. Dere E., Kart-Teke E., Huston J.P., De Souza Silva M.A. The case for episodic memory in animals. Neurosci Biobehav Rev 2006, 30:1206-1224.
26. Gacar N., Mutlu O., Utkan T., Komsuoglu Celikyurt I., Gocmez S.S., Ulak G. Beneficial effects of resveratrol on scopolamine but not mecamylamine induced memory impairment in the passive avoidance and Morris water maze tests in rats. Pharmacol Biochem Behav 2011, 99:316-323.
27. Monleón S., Urquiza A., Carmen Arenas M., Vinader-Caerols C., Parra A. Chronic administration of fluoxetine impairs inhibitory avoidance in male but not female mice. Behav Brain Res 2002, 136:483-488.
28. McGaugh J.L., Izquierdo I. The contribution of pharmacology to research on the mechanism of memory formation. Trends Phramacol Sci 2000, 21:208-210.
29. Cain D.P., Saucier D., Hall J., Hargreaves E.L., Boon F. Detailed behavioral analysis of water maze acquisition under APV or CNQX: contribution of sensorimotor disturbances to drug-induced acquisition deficits. Behav Neurosci 1996, 110:86-102.
30. Saucier D., Hargreaves E.L., Boon F., Vanderwolf C.H., Cain D.P. Detailed behavioral analysis of water maze acquisition under systemic NMDA or muscarinic antagonism: nonspatial pretraining eliminates spatial learning deficits. Behav Neurosci 1996, 110:103-116.
31. Hodges D.B., Lindner M.D., Hogan J.B., Jones K.M., Markus E.J. Scopolamine induced deficits in a battery of rat cognitive tests: comparisons of sensitivity and specificity. Behav Pharmacol 2009, 20:237-251.
32. Shiotsuki H., Yoshimi K., Shimo Y., Funayama M., Takamatsu Y., Ikeda K., et al. A rotarod test for evaluation of motor skill learning. J Neurosci Methods 2010, 189:180-185.
33. Kimura Y., Ohue M., Kitaura T., Kihira K. Amnesic effects of the anticholinergic drugs, trihexyphenidyl and biperiden: differences in binding properties to the brain muscarinic receptor. Brain Res 1999, 834:6-12.
34. Misik J., Kassa J. A comparison of cholinesterase inhibitors in the treatment of quinuclidinyl benzilate-induced behavioural deficit in rats performing the multiple T-maze. J Appl Biomed 2014, 10.1016/j.jab.2014.01.006.
35. Vance W.B. Observations on the role of salivary secretions in the regulation of food and fluid intake in the white rat. Psychol Monogr 1965, 79:1-22.
36. Roldan G., Bolaños-Badillo E., González-Sánchez H., Quirarte G.L., Prado-Alcalá R.A. Selective M1 muscarinic receptor antagonists disrupt memory consolidation of inhibitory avoidance in rats. Neurosci Lett 1997, 230:93-96.
37. Levey A.I. Immunological locarization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 1993, 52:441-448.
38. Drever B.D., Riedel G., Platt B. The cholinergic system and hippocampal plasticity. Behav Brain Res 2011, 221:505-514.
39. Li M., Yasuda R.P., Wall S.J., Wellstein A., Wolfe B.B. Distribution of m2 muscarinic receptors in rat brain using antisera selective for m2 receptors. Mol Pharmacol 1991, 40:28-35.
40. Quirion R., Wilson A., Rowe W., Aubert I., Richard J., Doods H., et al. Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired. J Neurosci 1995, 15:1455-1462.
41. Hasselmo M.E., McGaughy J. High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation. Prog Brain Res 2004, 145:207-231.
42. Kukolja J., Thiel C.M., Fink G.R. Cholinergic stimulation enhances neural activity associated with encoding but reduces neural activity associated with retrieval in humans. J Neurosci 2009, 29:8119-8128.
43. Van der Zee E.A., Platt B., Riedel G. Acetylcholine: future research and perspectives. Behav Brain Res 2011, 221:583-586.
44. Jackson J.J., Soliman M.R. Effects of tacrine (THA) on spatial reference memory and cholinergic enzymes in specific rat brain regions. Life Sci 1996, 58:47-54.
45. Barros D.M., Mello e Souza T., De David T., Choi H., Aguzzoli A., Madche C., et al. Simultaneous modulation of retrieval by dopaminergic D(1), beta-noradrenergic, serotonergic-1A and cholinergic muscarinic receptors in cortical structures of the rat. Behav Brain Res 2001, 124:1-7.
46. Liu W.F., Hu N.W., Beaton J.M. Biphasic effects of 3-quinuclidinyl benzilate on spontaneous motor activity in mice. Psychopharmacology 1984, 84:486-488.
47. Gibson R.E., Zeeberg B.R., Melograna J.M., Wang T.F., Ruch J., Braun A., et al. In vivo dissociation kinetics of [3H]quinuclidinyl benzilate: relationship to muscarinic receptor concentration and in vitro kinetics. Brain Res 1991, 553:110-116.
48. Beiko J., Candusso L., Cain D.P. The effect of nonspatial water maze pretraining in rats subjected to serotonin depletion and muscarinic receptor antagonism: a detailed behavioural assessment of spatial performance. Behav Brain Res 1997, 88:201-211.